<div id="readability-page-1"><p>Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) dropped 9.5% during trading on Monday . The stock traded as low as $10.94 and last traded at $10.79. Approximately 766,760 shares changed hands during mid-day trading, an increase of 19% from the average daily volume of 642,363 shares. The stock had previously closed at $11.92.</p><div><p><span></span><span>Get <strong>Cullinan Therapeutics</strong> alerts:</span></p></div><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities analysts have recently commented on CGEM shares. HC Wainwright raised their target price on shares of Cullinan Therapeutics from $24.00 to $26.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, November 20th. Wall Street Zen raised shares of Cullinan Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 22nd. Wedbush boosted their price target on Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, December 9th. Morgan Stanley dropped their price objective on shares of Cullinan Therapeutics from $35.00 to $28.00 and set an &#34;overweight&#34; rating on the stock in a report on Monday, August 18th. Finally, Zacks Research upgraded shares of Cullinan Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, September 16th. Six analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has assigned  a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $28.29.</p><p><b>View Our Latest Stock Report on Cullinan Therapeutics</b></p><h2>Cullinan Therapeutics Stock Performance</h2><p>The stock has a market cap of $639.25 million, a price-to-earnings ratio of -3.27 and a beta of -0.11. The business's 50 day moving average is $8.99 and its 200-day moving average is $8.06. </p><p>Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.77) earnings per share for the quarter, beating analysts' consensus estimates of ($0.95) by $0.18.  Sell-side analysts anticipate that  Cullinan Therapeutics, Inc. will post -3.04 EPS for the current fiscal year. </p><h2>Insider Buying and Selling</h2><p>In other news, major shareholder Lynx1 Capital Management Lp acquired 626,043 shares of the company's stock in a transaction that occurred on Thursday, October 9th. The stock was purchased at an average price of $6.70 per share, with a total value of $4,194,488.10. Following the completion of the acquisition, the insider owned 8,271,786 shares of the company's stock, valued at $55,420,966.20. This trade represents a 8.19% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jennifer Michaelson sold 4,000 shares of the stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $12.30, for a total transaction of $49,200.00. Following the completion of the sale, the insider directly owned 138,004 shares of the company's stock, valued at approximately $1,697,449.20. This trade represents a 2.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders acquired a total of 1,874,057 shares of company stock worth $13,325,286 over the last three months. Corporate insiders own  6.07% of the company's stock. </p><h2>Institutional Investors Weigh In On Cullinan Therapeutics</h2><p>A number of institutional investors have recently modified their holdings of the company. Brooklyn Investment Group acquired a new position in  Cullinan Therapeutics in the 1st quarter valued at about $34,000.  Tower Research Capital LLC TRC raised its stake in  Cullinan Therapeutics by 44.6% in the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company's stock valued at $62,000 after buying an additional 2,523 shares in the last quarter.  SG Americas Securities LLC purchased a new position in shares of  Cullinan Therapeutics in the 3rd quarter valued at about $62,000.  Y Intercept Hong Kong Ltd purchased a new position in  Cullinan Therapeutics in the second quarter valued at approximately $84,000.  Finally, Inscription Capital LLC acquired a new stake in  Cullinan Therapeutics during the 3rd quarter worth $67,000. 86.31% of the stock is owned by institutional investors and hedge funds. </p><h2>Cullinan Therapeutics Company Profile</h2> (Get Free Report)<p>Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Cullinan Therapeutics</li><li>What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story</li><li>Is Nutanix the Best Comeback Trade Left in 2025? The Setup Says Yes</li><li>Insider Trading - What You Need to Know</li><li>The Vertiv Pullback: Ignore the Noise, Buy the Data</li><li>How to Use High Beta Stocks to Maximize Your Investing Profits</li><li>Insiders Buy Natural Gas Stocks: 2 for the Watchlist</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Cullinan Therapeutics Right Now?</h2><p>Before you consider Cullinan Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.</p><p>While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CGEM

<p>Shares of Cullinan Therapeutics (NASDAQ:CGEM) fell 9.5% to $10.79 with increased trading volume. Analysts have mixed ratings, with some upgrading their target prices. The company reported better-than-expected quarterly earnings. Insider trading activity included significant purchases and sales. Institutional investors have also modified their holdings. Cullinan focuses on developing oncology therapies, with several programs in clinical trials.</p>

Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 9.5% - What's Next?